Cara Therapeutics (CARA)
Needham analyst Joseph Stringer reiterated a Buy rating on Cara Therapeutics today and set a price target of $26.00. The company’s shares closed last Thursday at $9.37.
According to TipRanks.com, Stringer is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Cara Therapeutics is a Moderate Buy with an average price target of $28.00.
BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra today and set a price target of $272.00. The company’s shares closed last Thursday at $125.34, close to its 52-week low of $114.87.
According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of
Currently, the analyst consensus on Penumbra is a Strong Buy with an average price target of $250.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CARA:
- Belo Sun Announces 2022 AGM Voting Results
- BOUSSARD & GAVAUDAN HOLDING LIMITED (EUR) : Transaction in Own Shares
- Blackhawk Network Partners with Restaurant.com to Offer eGifts at GiftCardMall.com and Other Major Digital Retailers
- Total Voting Rights
- CPS Announces Doubling Of Credit Facility To $200 Million